	US 12,214,017 B2
	GLP-1 compositions and uses thereof
Eva Horn Moeller, Alleroed (DK); Michael Duelund Soerensen, Soeborg (DK); and Joakim Lundqvist, Malmoe (SE)
Assigned to Novo Nordisk A/S, Bagsvaerd (DK)
Filed by Novo Nordisk A/S, Bagsvaerd (DK)
Filed on Jan. 30, 2024, as Appl. No. 18/427,270.
Application 18/427,270 is a continuation of application No. 18/226,405, filed on Jul. 26, 2023.
Application 18/226,405 is a continuation of application No. 17/115,773, filed on Dec. 8, 2020, granted, now 11,752,198, issued on Sep. 12, 2023.
Application 17/115,773 is a continuation of application No. 16/774,666, filed on Jan. 28, 2020, granted, now 10,888,605, issued on Jan. 12, 2021.
Application 16/774,666 is a continuation of application No. PCT/EP2018/072835, filed on Aug. 24, 2018.
Claims priority of application No. 17187676 (EP), filed on Aug. 24, 2017.
Prior Publication US 2024/0216475 A1, Jul. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/26 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01)

CPC A61K 38/26 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01)]

9 Claims

1. A liquid pharmaceutical composition comprising:

semaglutide;

wherein said composition

(a) does not contain phenol; and

(b) is administered parenterally; and

(c)(i) is an aqueous solution comprising at least 60% (w/w) water or (ii)

further comprises one or more pharmaceutically acceptable excipients selected from the group consisting of a buffer or an isotonic agent; and

wherein the semaglutide is in the range of 0.01 mg/ml-10.0 mg/ml; and

wherein the pH of the composition is in between 7.0 and 7.8.